Search results for "Phase II as Topic"

showing 5 items of 25 documents

Cetuximab in squamous cell head and neck carcinomas.

2007

The epidermal growth factor receptor (EGFR) antagonist, cetuximab, has recently been shown to enhance the effects of radiotherapy, and reports to date indicate that this effect occurs without any change in the pattern and severity of toxicity usually associated with head and neck radiation and/or chemotherapy (CT) administration. Moreover, several studies have reported that the expression of EGFR is strongly linked to poor outcome in patients undergoing therapy. Therefore, the presence of the EGFR in almost all cases of head and neck carcinoma offers a new therapeutic opportunity to most patients. In this paper, we report a review of the major studies dealing with the use of cetuximab in ad…

Oncologymedicine.medical_specialtyRadiation-Sensitizing Agentsmedicine.medical_treatmentCetuximabAntineoplastic AgentsAntibodies Monoclonal HumanizedClinical Trials Phase II as TopicInternal medicinemedicineCarcinomaAnimalsHumansEpidermal growth factor receptorSquamous epithelial cellCetuximabbiologyClinical Trials Phase I as Topicbusiness.industryHead and neck cancerAntibodies MonoclonalHematologymedicine.diseaseHead and neck squamous-cell carcinomaChemotherapy regimenRadiation therapyneck carcinomasmedicine.anatomical_structureOncologyHead and Neck Neoplasmsbiology.proteinCarcinoma Squamous CellNeoplasm Recurrence Localbusinessmedicine.drugAnnals of oncology : official journal of the European Society for Medical Oncology
researchProduct

Erythropoietin and subarachnoid hemorrhage.

2010

Pathologymedicine.medical_specialtySubarachnoid hemorrhageErytTime Factorserythropoietin subarachnoid hemorragelaw.inventionAnimals; Brain Ischemia; Clinical Trials; Phase II as Topic; Disease Models; Animal; Eryt; Humans; Neuroprotective Agents; Randomized Controlled Trials as Topic; Recombinant Proteins; Subarachnoid Hemorrhage; Time Factors; hropoietinBrain IschemiaBrain ischemialawmedicineAnimalsHumansClinical TrialsRandomized Controlled Trials as TopicSettore MED/27 - Neurochirurgiabusiness.industryAnimalPhase II as TopicGeneral MedicinehropoietinSubarachnoid Hemorrhagemedicine.diseaseRecombinant ProteinsNeuroprotective AgentsErythropoietinDisease ModelsRecombinant DNAbusinessmedicine.drug
researchProduct

Looking for the best immune-checkpoint inhibitor in pre-treated NSCLC patients: An indirect comparison between nivolumab, pembrolizumab and atezolizu…

2017

Immune-checkpoint inhibitors represent the new standard of care in patients with advanced NSCLC who progressed after first-line treatment. This work aim to assess any difference in both efficacy and safety profiles among Nivolumab, Pembrolizumab and Atezolizumab in pre-treated NSCLC patients. Randomized clinical trials comparing immune-checkpoint inhibitor versus docetaxel in pre-treated patients with advanced NSCLC were included and direct comparison meta-analysis of selected trials have been performed. Subsequently the summary estimates of Nivolumab, Pembrolizumab and Atezolizumab emerging from the direct meta-analysis were selected to provide the pooled estimates of hazard ratio (HR) and…

atezolizumabCancer ResearchLung NeoplasmsAntineoplastic AgentsDocetaxelAntibodies Monoclonal HumanizedNSCLCClinical Trials Phase II as TopicCostimulatory and Inhibitory T-Cell ReceptorsCarcinoma Non-Small-Cell LungPDL1HumansRandomized Controlled Trials as TopicnivolumabIncidenceAntibodies MonoclonalPneumoniaSurvival AnalysisPD1Treatment OutcomeClinical Trials Phase III as TopicOncologyimmune-checkpointTaxoidsatezolizumab; immune-checkpoint; nivolumab; NSCLC; PD1; PDL1; pembrolizumab; Oncology; Cancer Researchpembrolizumab
researchProduct

Recent clinical evidence on metronomic dosing in controlled clinical trials: a systematic literature review.

2020

Introduction: Metronomic dosing is used to give continuous chemotherapy at low doses. The low doses have minimal side effects and may enable cancer treatment to be remodeled toward the management o...

medicine.medical_specialtymedicine.medical_treatmentAntineoplastic Agents030218 nuclear medicine & medical imaging03 medical and health sciences0302 clinical medicineClinical Trials Phase II as TopicNeoplasmsAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansRadiology Nuclear Medicine and imagingDosingIntensive care medicineRandomized Controlled Trials as TopicChemotherapybusiness.industryLow doseHematologyGeneral MedicineProgression-Free SurvivalCancer treatmentClinical trialSurvival RateSystematic reviewOncologyClinical Trials Phase III as TopicClinical evidence030220 oncology & carcinogenesisAdministration MetronomicbusinessActa oncologica (Stockholm, Sweden)
researchProduct

Rationale and design of the EMBRACE STEMI Study: A phase 2a, randomized, double-blind, placebo-controlled trial to evaluate the safety, tolerability …

2012

Background Although significant efforts have been made to improve ST-segment elevation myocardial infarction (STEMI) outcomes by reducing symptom-onset-to-reperfusion times, strategies to decrease the clinical impact of ischemic reperfusion injury have demonstrated limited success. Bendavia, an intravenously administered mitochondrial targeting peptide, has been shown to reduce myocardial infarct size and attenuate coronary no-reflow in experimental modelswhen given before reperfusion. Design The EMBRACE STEMI study is a phase 2a, randomized, double-blind, placebo-controlled trial enrolling 300 patients with a first-time anterior STEMI and an occluded proximal or mid–left anterior descendin…

medicine.medical_specialtymedicine.medical_treatmentMyocardial InfarctionPlacebo-controlled studyMyocardial Reperfusion InjuryPlaceboClinical Trials Phase II as TopicInternal medicinemedicineClinical endpointHumansInfusions Intra-ArterialST segmentcardiovascular diseasesMyocardial infarctionRandomized Controlled Trials as Topicbusiness.industryPatient SelectionPercutaneous coronary interventionmedicine.diseaseResearch DesignConventional PCICardiologyNo-Reflow PhenomenonStentsCardiology and Cardiovascular MedicinebusinessOligopeptidesReperfusion injuryAmerican Heart Journal
researchProduct